Company attributes
Other attributes
Oncos Therapeutics is a clinical-stage biotechnology company that has broad pipelines addressing the immuno-oncology market, which is expected to grow to USD 30-35 billion over the next decade. Oncos Therapeutics has joined forces with Targovax to become a larger and more visible Nordic immuno-oncology player with a more extensive portfolio.
Its lead clinical candidate, ONCOS-102, is a genetically modified oncolytic adenovirus that has been engineered to selectively infect cancer cells and activate the immune system to tackle cancer. On the back of encouraging data in several indications, in monotherapy and in multiple combination, the next development steps for ONCOS-102 will involve a clinical trial with registration intent in checkpoint inhibitor refractory melanoma.
